azd-3514
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01162395)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Androgen ReceptorMODULATOR
AR modulator
Selective androgen receptor inhibitor and down-regulator (SARD). AZD3514 binds to AR, inhibits its nuclear translocation, ligand-dependent and independent transcriptional activity and is able to induce AR down-regulation in vitro and in vivo. .Discontinued, safety/efficacy reasons.
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1- Mol. weight
- 519.57 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2346976 ↗
Also known as
- azd3514
- azd3514
- azd3514
- azd-3514
- azd-3514
- cs-1443
- cs-1443
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01351688 | Phase 1 | Aug 1, 2011 | AstraZeneca, Kitasato University |
| NCT01162395 | Phase 1 | Aug 1, 2010 | AstraZeneca, The Christie NHS Foundation Trust |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 2 | 1 | 2010 |
| Kitasato University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| The Christie NHS Foundation Trust | Academic/Hospital | 1 | 0 | 1 | 2010 |
3 organizations
Page 1 / 1